Patents by Inventor Norbert Peter KOPER

Norbert Peter KOPER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYD985 treatment of T-DM1 refractory cancer patients
    Patent number: 10821191
    Abstract: The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patients.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: November 3, 2020
    Assignee: Byondis B.V.
    Inventors: Gerrit Voortman, Norbert Peter Koper
  • SYD985 TREATMENT OF T-DM1 REFRACTORY CANCER PATIENTS
    Publication number: 20180280533
    Abstract: The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patients.
    Type: Application
    Filed: September 21, 2016
    Publication date: October 4, 2018
    Inventors: Gerrit VOORTMAN, Norbert Peter KOPER